About Us / Blogs

Location:Home > About Us > Blogs >

  • CRISPR-Nanopore Sequencing Combo Could Revolutionize Cancer Gene Identification

    The speed and accuracy w ith which current sequencing platforms can produce results are quite staggering compared to methodologies that were being utilized less than ten years ago. Yet, when it comes to making clinical decisions with respect to cancerous tumors, sequencing assays …

  • The first CRISPR gene therapy is safe

    In November, researchers announced the results of the first US CRISPR gene therapy. Now the data are out in a peer-reviewed paper, and here are comments on the results from leading researcher Carl June and experts in the field.

  • Preliminary Results Point to Success of In Vivo Gene Editing

    Two studies show signs that the introduced DNA is functioning, but it’s too early to know if patients actually benefit.

  • Reproductive genome from the laboratory

    Synthetic biology researchers have developed a genome the size of a minimal cell that can copy itself.

  • Genome stability: Intricate process of DNA repair discovered

    An elaborate system of filaments, liquid droplet dynamics and protein connectors enables the repair of some damaged DNA in the nuclei of cells, researchers have found. The findings further challenge the belief that broken DNA floats aimlessly -- and highlight the value of cross-di…

  • Molecular 'switch' reverses chronic inflammation and aging

    Scientists have identified a molecular 'switch' that controls the immune machinery responsible for chronic inflammation in the body. The finding could lead to new ways to halt or even reverse many age-related conditions, from from Alzheimer's and Parkinson's to diabetes and cancer…

  • Base Editing Promise in Treating a Mouse Model of Progeria

    David Liu, PhD, presents in vivo results showing proof-of-principle of base editing in correcting the gene defect responsible for a premature aging genetic disorder in mice.

  • CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial

    In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.

  • Successful T cell engineering with gene scissors

    The idea of genetically modifying a patient's own immune cells and deploying them against infections and tumors has been around since the 1980s. But to this day modified T cells are still not as effective as natural T cells and have been only been of limited clinical value. Using …


Contact us